Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: A case-based approach

Annals of Pharmacotherapy

Volumn 40, Issue 9, 2006, Pages 1558-1571

  Nutescu, Edith A ^a   Wittkowsky, Ann K ^b,c   Dobesh, Paul P ^d   Hawkins, David W ^e   Dager, William E ^f,g  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e SOUTHERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Direct thrombin inhibitors; Factor xa inhibitors; Heparin; Low molecular weight heparin; Venous thromboembolism; Warfarin

Indexed keywords

ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN NECROSIS; VENOUS THROMBOEMBOLISM;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33748304287     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G577     Document Type: Article

References (98)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):338S-400S.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93. DOI 10.1001/archinte.158.6.585
3. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-6. DOI 10.1001/archinte.154.8.861
4. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
5. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 200(1; 160:769-74. DOI 10.1001/archinte.160.6.769
6. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;339:93-104. DOI 10.1056/NEJM199807093390207
7. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:19-16. DOI 10.1161/01.CIR.0000046771.12875.6C
8. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8. DOI 10.1001/archinte. 164.9.963
9. Turpie AG, Chin BS, Lip GY. ABC of antithrombotic therapy: venous thromboembolism: treatment strategies. BMJ 2002;325:948-50. DOI 10.1136/bmj.325.7370.948
10. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771-4. DOI 10.1001/archinte.149.4.771
11. Snook GA, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res 1981;155:21-4.
12. Agnelli G, Cosmi B, Di Filippo P, et al. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992;67:203-8.
13. Todd CJ, Freeman CJ, Camilleri-Ferrante C, et al. Differences in mortality after fracture of hip: the east Anglian audit. Br Med J 1995;310:904-8.
14. Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis. Clin Orthop Relat Res 1989;242:212-31.
15. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-8.
16. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl): 179S-87S. DOI 10.1378/chest. 126.1.179
17. Package insert, Innohep (tinzaparin sodium). Boulder, CO: Pharmion, January 2003.
18. Package insert. Lovenox (enoxaparin sodium). Bridgewater, NJ: Aventis Pharmaceuticals, July 2004.
19. Package insert. Arixtra (fondaparinux sodium). Research Triangle Park, NC: GlaxoSmithKline, May 2005.
20. Package insert. Heparin sodium injection. Kalamazoo, MI: Pharmacia & Upjohn, December 2000.
21. Package insert. Warfarin sodium tablets. Pomona, NY: Barr Laboratories, November 2002.
22. Package insert. Fragmin (dalteparin sodium). Kalamazoo, MI: Pharmacia & Upjohn, December 2003.
23. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):401S-28S. DOI 10.1378/chest. 126.3_suppl.401S
24. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S. DOI 10.1378/chest.119.1_suppl.8S
25. Walenga JM, Frenkel EP, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Hematol Oncol Clin North Am 2003; 17:259-82. viii-ix. DOI 10.1016/S0889-8588(02) 00088-6
26. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003;163:759-68. DOI 10.1001/archinte.163.7.759
27. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134: 191-202.
28. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-103. DOI 10.1046/j.1365-2168.1997.d01-3882.x
29. Bergqvist D, Agnelli G, Cohen AT. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-80. DOI 10.1056/NEJMoa012385
30. Agnelli G, Bergqvist D, Cohen AT, Callus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-20. DOI 10.1002/bjs.5154
31. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304. DOI 10.1056/NEJMoa011100
32. Geerts WH, Heit JA, Clagett GP. et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):132S-75S. DOI 10.1378/chest.119. 1_suppl.132S
33. Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev 2002: CD000305.DOI 10.1002/14651858. CD000305
34. Eriksson BI, Lassen MR. Duration of prophylaxis against venous throm-boembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-42. DOI 10.1001/archinte.163.11,1337
35. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800. DOI 10.1056/NEJM199909093411103
36. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-9.
37. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21. DOI 10.1067/mhj.2003.189
38. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9. DOI 10.1161/01. CIR.0000138928.83266.24
39. Cohen AT, Davidson BL, Callus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332: 325-9. Epub 2005 Jan 26. DOI 10.1136/bmj.38733.466748.7C
40. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337:657-62. DOI 10.1056/NEJM199709043371001
41. Could MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
42. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8. DOI 10.1001/archinte.160.2.181
43. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73.
44. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337:663-9. DOI 10.1056/NEJM199709043371002
45. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160: 229-36. DOI 10.1001/archinte,160.2.229
46. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702. DOl 10.1056/NEJMoa035451
47. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165: 733-8. DOI 10.1001/archinte.165.7.733
48. Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury 1999;30:605-7. DOI 10.1016/50020-1383(99)00163-1
49. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE 1. J Thromb Haemost 2003;1:41-7. DOI 10.1046/j.1538-7836.2003.00034.x
50. Eriksson BI, Agnelli G, Cohen AT. et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6. DOI 10.1111/j.1538-7836.2003. 00494.x
51. Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery 2001:130:1-12. DOI 10.1067/msy.2001.114558
52. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13. DOI 10.1016/0002-9343(87)90004-0
53. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003;124(suppl):379S-85S. DOI 10.1378/chest.124.6_suppl.379S
54. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003;90:364-6.
55. Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006;21:36-45.
56. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993:329:1370-6. DOI 10.1056/NEJM199311043291902
57. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40. DOI 10.1302/0301-620X.81B5.10316
58. De Wal H, Su E, Hiebert R, Di Cesare P. Factors influencing post-operative surgical drain output and time to a dry wound following total knee arthroplasty (abstract). Presented at: American Academy of Orthopaedic Surgeons, New Orleans, LA, February 5-9, 2003.
59. Sanchez-Ballaster J, Smith MG, Kershaw S. Wound infection in the management of hip fractures: a comparison between subcutaneous low-molecular-weight heparin and no thromboprophylaxis (abstract). Presented at: American Academy of Orthopaedic Surgeons, New Orleans, LA, February 5-9, 2003.
60. Waldman BJ. Advancements in minimally invasive total hip arthroplasty. Orthopedics 2003;26(suppl 8):S833-6.
61. Peters PC Jr, Nutescu E, Andersen J. Wound pharmacobiology. Orthopedics 2003;26(8 suppl):s837-42.
62. Dager WE, Andersen J, Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 2004;24(suppl):88S-94S.
63. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124(suppl):386S-92S. DOI 10.1378/chest.124.6_suppl.386S
64. Thaler HW, Roller RE, Greiner N, Sim E, Korninger C. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma 2001;51:518-21.
65. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700. DOI 10.1056/NEJM199609053351002
66. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966-71. DOI 10.1001/archinte.162.17. 1966
67. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.001 10.1056/NEJM 199603143341101
68. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682-7.001 10.1056/ NEJM199603143341102
69. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
70. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53. DOI 10.1056/NEJMoa025313
71. Hull R, Pineo G, Mah A, Brant RF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium (abstract). Blood 2002; 100:148a.
72. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858-69.
73. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123-9. DOI 10.1200/JCO.2005.03.133
74. Warkentin TE, Greinacher A, Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):311S-37S. DOI 10.1378/chest.126.1.311
75. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003;4:919-40. DOI 10.1517/14656566.4.6.919
76. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164:66-70. DOI 10.1001/archinte.164.1.66
77. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55. DOI 10.1046/j.1365-2141.2003.04334.x
78. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
79. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-9.
80. Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997;17:325-41.
81. Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. J Am Coll Surg 1998;187:641-58. DOI 10.1016/51072-7515(98) 00255-5
82. Amiral J, Lormeau JC, Marfaing-Koka A. et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-7.
83. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-44. DOI 10.1182/blood-2004-05-2010
84. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):265S-86S. DOI 10.1378/chest.126.3_suppl.265S
85. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36:489-503. DOI 10.1345/aph.1A204
86. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002;57:751-8. DOI 10.1007/s00228-001-0392-7
87. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-81. DOI 10.1016/S0049-3848(00)00399-6
88. D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003;1:2452-3. DOI 10.1046/j.1538-7836.2003.0468c.x
89. Kuo KHM, Kovacs MJ. Successful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux (abstract). Blood 2003;102:319a.
90. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995;11:511-4.
91. Cohen A, Alikhan R, Arcelus JI, et al. A risk assessment model for identifying medical patients who should receive thromboprophylaxis (abstract). J Thromb Haemost 2003;(suppl 1):OC437.
92. Samama M, Dahl OE. Mismetti P, etal. Individualizing the risk of venous thromboembolism in medical and surgical patients: development of the decision matrix for VTE prophylaxis (abstract). J Thromb Haemost 2003;1(supp1):OC436.
93. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-7.
94. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996;76:529-34.
95. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996;26:127-39.
96. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996;26(suppl 2):49-56.
97. Harenberg J, Schomaker U, Flosbach CW. Enoxaparin is superior to unfractionated heparin in the prevention of venous thromboembolic events in medical patients at increased thromboembolic risk (abstract). Blood 1999;94(suppl 1):399a.
98. Hillborn M, Erila T, Sotaniemi K, et al. Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke (abstract). Blood 1999:94(suppl 1):183a.